<VariationArchive VariationID="1810401" VariationName="NM_025137.4(SPG11):c.6738dup (p.Glu2247Ter)" VariationType="Duplication" Accession="VCV001810401" Version="29" RecordType="classified" NumberOfSubmissions="3" NumberOfSubmitters="3" DateLastUpdated="2024-05-08" DateCreated="2023-01-15" MostRecentSubmission="2024-02-20">
  <RecordStatus>current</RecordStatus>
  <Species>Homo sapiens</Species>
  <ClassifiedRecord>
    <SimpleAllele AlleleID="1867414" VariationID="1810401">
      <GeneList>
        <Gene Symbol="SPG11" FullName="SPG11 vesicle trafficking associated, spatacsin" GeneID="80208" HGNC_ID="HGNC:11226" Source="submitted" RelationshipType="within single gene">
          <Location>
            <CytogeneticLocation>15q21.1</CytogeneticLocation>
            <SequenceLocation Assembly="GRCh38" AssemblyAccessionVersion="GCF_000001405.38" AssemblyStatus="current" Chr="15" Accession="NC_000015.10" start="44562696" stop="44663662" display_start="44562696" display_stop="44663662" Strand="-" />
            <SequenceLocation Assembly="GRCh37" AssemblyAccessionVersion="GCF_000001405.25" AssemblyStatus="previous" Chr="15" Accession="NC_000015.9" start="44854893" stop="44955875" display_start="44854893" display_stop="44955875" Strand="-" />
          </Location>
          <OMIM>610844</OMIM>
        </Gene>
      </GeneList>
      <Name>NM_025137.4(SPG11):c.6738dup (p.Glu2247Ter)</Name>
      <CanonicalSPDI>NC_000015.10:44567439:AA:AAA</CanonicalSPDI>
      <VariantType>Duplication</VariantType>
      <Location>
        <CytogeneticLocation>15q21.1</CytogeneticLocation>
        <SequenceLocation Assembly="GRCh38" AssemblyAccessionVersion="GCF_000001405.38" forDisplay="true" AssemblyStatus="current" Chr="15" Accession="NC_000015.10" start="44567439" stop="44567440" display_start="44567439" display_stop="44567440" variantLength="1" positionVCF="44567439" referenceAlleleVCF="C" alternateAlleleVCF="CA" />
        <SequenceLocation Assembly="GRCh37" AssemblyAccessionVersion="GCF_000001405.25" AssemblyStatus="previous" Chr="15" Accession="NC_000015.9" start="44859637" stop="44859638" display_start="44859637" display_stop="44859638" variantLength="1" positionVCF="44859637" referenceAlleleVCF="C" alternateAlleleVCF="CA" />
      </Location>
      <ProteinChange>E2247*</ProteinChange>
      <ProteinChange>E2134*</ProteinChange>
      <HGVSlist>
        <HGVS Assembly="GRCh38" Type="genomic, top-level">
          <NucleotideExpression sequenceAccessionVersion="NC_000015.10" sequenceAccession="NC_000015" sequenceVersion="10" change="g.44567441dup" Assembly="GRCh38">
            <Expression>NC_000015.10:g.44567441dup</Expression>
          </NucleotideExpression>
        </HGVS>
        <HGVS Assembly="GRCh37" Type="genomic, top-level">
          <NucleotideExpression sequenceAccessionVersion="NC_000015.9" sequenceAccession="NC_000015" sequenceVersion="9" change="g.44859639dup" Assembly="GRCh37">
            <Expression>NC_000015.9:g.44859639dup</Expression>
          </NucleotideExpression>
        </HGVS>
        <HGVS Type="genomic">
          <NucleotideExpression sequenceAccessionVersion="NG_008885.1" sequenceAccession="NG_008885" sequenceVersion="1" change="g.101239dup">
            <Expression>NG_008885.1:g.101239dup</Expression>
          </NucleotideExpression>
        </HGVS>
        <HGVS Type="coding">
          <NucleotideExpression sequenceAccessionVersion="NM_001160227.2" sequenceAccession="NM_001160227" sequenceVersion="2" change="c.6399dup">
            <Expression>NM_001160227.2:c.6399dup</Expression>
          </NucleotideExpression>
          <ProteinExpression sequenceAccessionVersion="NP_001153699.1" sequenceAccession="NP_001153699" sequenceVersion="1" change="p.Glu2134Ter">
            <Expression>NP_001153699.1:p.Glu2134Ter</Expression>
          </ProteinExpression>
          <MolecularConsequence ID="SO:0001587" Type="nonsense" DB="SO" />
        </HGVS>
        <HGVS Type="coding">
          <NucleotideExpression sequenceAccessionVersion="NM_001411132.1" sequenceAccession="NM_001411132" sequenceVersion="1" change="c.6593dup">
            <Expression>NM_001411132.1:c.6593dup</Expression>
          </NucleotideExpression>
          <ProteinExpression sequenceAccessionVersion="NP_001398061.1" sequenceAccession="NP_001398061" sequenceVersion="1" change="p.Glu2199Terfs">
            <Expression>NP_001398061.1:p.Glu2199Terfs</Expression>
          </ProteinExpression>
          <MolecularConsequence ID="SO:0001589" Type="frameshift variant" DB="SO" />
          <MolecularConsequence ID="SO:0001587" Type="nonsense" DB="SO" />
        </HGVS>
        <HGVS Type="coding">
          <NucleotideExpression sequenceAccessionVersion="NM_025137.4" sequenceAccession="NM_025137" sequenceVersion="4" change="c.6738dup" MANESelect="true">
            <Expression>NM_025137.4:c.6738dup</Expression>
          </NucleotideExpression>
          <ProteinExpression sequenceAccessionVersion="NP_079413.3" sequenceAccession="NP_079413" sequenceVersion="3" change="p.Glu2247Ter">
            <Expression>NP_079413.3:p.Glu2247Ter</Expression>
          </ProteinExpression>
          <MolecularConsequence ID="SO:0001587" Type="nonsense" DB="SO" />
        </HGVS>
        <HGVS Type="coding">
          <NucleotideExpression sequenceAccessionVersion="NM_001160227.1" sequenceAccession="NM_001160227" sequenceVersion="1" change="c.6399dup">
            <Expression>NM_001160227.1:c.6399dup</Expression>
          </NucleotideExpression>
        </HGVS>
      </HGVSlist>
    </SimpleAllele>
    <RCVList>
      <RCVAccession Title="NM_025137.4(SPG11):c.6738dup (p.Glu2247Ter) AND Hereditary spastic paraplegia 11" Accession="RCV002509888" Version="11">
        <ClassifiedConditionList TraitSetID="295">
          <ClassifiedCondition DB="MedGen" ID="C1858479">Hereditary spastic paraplegia 11</ClassifiedCondition>
        </ClassifiedConditionList>
        <RCVClassifications>
          <GermlineClassification>
            <ReviewStatus>criteria provided, multiple submitters, no conflicts</ReviewStatus>
            <Description DateLastEvaluated="2024-01-12" SubmissionCount="3">Pathogenic</Description>
          </GermlineClassification>
        </RCVClassifications>
      </RCVAccession>
    </RCVList>
    <Classifications>
      <GermlineClassification DateLastEvaluated="2024-01-12" NumberOfSubmissions="3" NumberOfSubmitters="3" DateCreated="2023-01-15" MostRecentSubmission="2024-02-20">
        <ReviewStatus>criteria provided, multiple submitters, no conflicts</ReviewStatus>
        <Description>Pathogenic</Description>
        <Citation Type="general">
          <ID Source="PubMed">19105190</ID>
        </Citation>
        <Citation Type="general">
          <ID Source="PubMed">20110243</ID>
        </Citation>
        <Citation Type="general">
          <ID Source="PubMed">22154821</ID>
        </Citation>
        <Citation Type="general">
          <ID Source="PubMed">26556829</ID>
        </Citation>
        <ConditionList>
          <TraitSet ID="295" Type="Disease" ContributesToAggregateClassification="true">
            <Trait ID="3739" Type="Disease">
              <Name>
                <ElementValue Type="Alternate">SPASTIC PARAPLEGIA, AUTOSOMAL RECESSIVE, COMPLICATED, WITH THIN CORPUS CALLOSUM</ElementValue>
                <XRef Type="MIM" ID="604360" DB="OMIM" />
              </Name>
              <Name>
                <ElementValue Type="Alternate">SPASTIC PARAPLEGIA, AUTOSOMAL RECESSIVE, WITH MENTAL IMPAIRMENT AND THIN CORPUS CALLOSUM</ElementValue>
                <XRef Type="MIM" ID="604360" DB="OMIM" />
              </Name>
              <Name>
                <ElementValue Type="Alternate">Spastic paraplegia 11, autosomal recessive</ElementValue>
                <XRef ID="Spastic+paraplegia+11/6677" DB="Genetic Alliance" />
              </Name>
              <Name>
                <ElementValue Type="Alternate">Spastic paraplegia 11</ElementValue>
              </Name>
              <Name>
                <ElementValue Type="Alternate">Hereditary spastic paraplegia mental impairment and thin corpus callosum</ElementValue>
              </Name>
              <Name>
                <ElementValue Type="Preferred">Hereditary spastic paraplegia 11</ElementValue>
                <XRef ID="MONDO:0011445" DB="MONDO" />
              </Name>
              <Name>
                <ElementValue Type="Alternate">Nakamura Osame syndrome</ElementValue>
              </Name>
              <Name>
                <ElementValue Type="Alternate">Autosomal recessive hereditary spastic paraplegia, mental impairment, and thin corpus callosum</ElementValue>
              </Name>
              <Name>
                <ElementValue Type="Alternate">Spastic paraplegia,  mental retardation and thin corpus callosum</ElementValue>
              </Name>
              <Symbol>
                <ElementValue Type="Alternate">HSP-TCC</ElementValue>
                <XRef Type="MIM" ID="604360" DB="OMIM" />
              </Symbol>
              <Symbol>
                <ElementValue Type="Alternate">SPG11</ElementValue>
                <XRef Type="MIM" ID="604360" DB="OMIM" />
              </Symbol>
              <AttributeSet>
                <Attribute Type="public definition">Spastic paraplegia 11 (SPG11) is characterized by progressive spasticity and weakness of the lower limbs frequently associated with the following: mild intellectual disability with learning difficulties in childhood and/or progressive cognitive decline; peripheral neuropathy; pseudobulbar involvement; and increased reflexes in the upper limbs. Less frequent findings include: cerebellar signs (ataxia, nystagmus, saccadic pursuit); retinal degeneration; pes cavus; scoliosis; and parkinsonism with characteristic brain MRI features that include thinning of the corpus callosum. Onset occurs mainly during infancy or adolescence (range: age 1-31 years) and in rare cases as late as age 60 years. Most affected individuals become wheelchair bound one or two decades after disease onset.</Attribute>
                <XRef ID="NBK1210" DB="GeneReviews" />
              </AttributeSet>
              <AttributeSet>
                <Attribute Type="GARD id" integerValue="4919" />
                <XRef ID="4919" DB="Office of Rare Diseases" />
              </AttributeSet>
              <Citation Type="review" Abbrev="GeneReviews">
                <ID Source="PubMed">20301389</ID>
                <ID Source="BookShelf">NBK1210</ID>
              </Citation>
              <XRef ID="2822" DB="Orphanet" />
              <XRef ID="C1858479" DB="MedGen" />
              <XRef ID="MONDO:0011445" DB="MONDO" />
              <XRef Type="MIM" ID="604360" DB="OMIM" />
            </Trait>
          </TraitSet>
        </ConditionList>
      </GermlineClassification>
    </Classifications>
    <ClinicalAssertionList>
      <ClinicalAssertion ID="5503591" SubmissionDate="2023-01-07" DateLastUpdated="2023-01-15" DateCreated="2023-01-15">
        <ClinVarSubmissionID localKey="NM_025137.3:c.6738_6739insT|OMIM:604360" submittedAssembly="GRCh37" />
        <ClinVarAccession Accession="SCV002818535" DateUpdated="2023-01-15" DateCreated="2023-01-15" Type="SCV" Version="1" SubmitterName="Department of Neurology, The Affiliated Hospital of Zunyi Medical University" OrgID="508902" OrganizationCategory="other" />
        <RecordStatus>current</RecordStatus>
        <Classification DateLastEvaluated="2023-01-04">
          <ReviewStatus>no assertion criteria provided</ReviewStatus>
          <GermlineClassification>Pathogenic</GermlineClassification>
          <Comment>This nucleotide variation could lead to the change of the codon compiling the amino acid Glu2247 into a stop codon (p. Glu 2247Ter), resulting in the premature termination of peptide chain synthesis, which was a nonsense variation.</Comment>
        </Classification>
        <Assertion>variation to disease</Assertion>
        <ObservedInList>
          <ObservedIn>
            <Sample>
              <Origin>inherited</Origin>
              <GeographicOrigin>Guizhou Province, China</GeographicOrigin>
              <Species TaxonomyId="9606">human</Species>
              <Age Type="minimum" age_unit="years">20</Age>
              <Age Type="maximum" age_unit="years">29</Age>
              <AffectedStatus>yes</AffectedStatus>
              <Gender>female</Gender>
            </Sample>
            <Method>
              <MethodType>clinical testing</MethodType>
              <ObsMethodAttribute>
                <Attribute Type="TestingLaboratory" dateValue="2018-05-07">Beijing Kangxu Institute of Medical Laboratory</Attribute>
              </ObsMethodAttribute>
            </Method>
            <ObservedData>
              <Attribute Type="VariantAlleles" integerValue="2" />
            </ObservedData>
          </ObservedIn>
        </ObservedInList>
        <SimpleAllele>
          <VariantType>Variation</VariantType>
          <AttributeSet>
            <Attribute Type="HGVS">NM_025137.3:c.6738_6739insT</Attribute>
          </AttributeSet>
        </SimpleAllele>
        <TraitSet Type="Disease">
          <Trait Type="Disease">
            <XRef DB="OMIM" ID="604360" Type="MIM" />
          </Trait>
        </TraitSet>
        <Comment>In silico analysis of the mutant sequences was performed. The pathogenic significance of mutations (c.6738_6739insT, c.5934_5935insTAACCTGGAA) was analyzed based on reference sequence NM_025137.3 and NP_079413.3 (SPG11 gene) by different software tools including MutationTaster (http://www. mutationtaster.org/), PolyPhen-2 (Polymorphism Phenotyping) (http://genetics.bwh.harvard.edu/pph2/), PROVEAN (Protein Variation Effect Analyzer) (http://provean. jcvi.org/index.php), and CADD (Combined Annotation ependent Depletion). The results of in silico analysis showed that the mutations predicated to be disease-causing variants by MutationTaster, probably damaging by PolyPhen-2, deleterious by PROVEAN, and deleterious and pathogenic by CADD (PHRED score 25 for both variants).</Comment>
        <SubmissionNameList>
          <SubmissionName>SUB12518422</SubmissionName>
        </SubmissionNameList>
      </ClinicalAssertion>
      <ClinicalAssertion ID="7329936" SubmissionDate="2023-04-28" DateLastUpdated="2023-11-04" DateCreated="2023-11-04">
        <ClinVarSubmissionID localKey="NM_001160227.1:c.6399dup|OMIM:604360" submittedAssembly="GRCh37" />
        <ClinVarAccession Accession="SCV003920828" DateUpdated="2023-11-04" DateCreated="2023-11-04" Type="SCV" Version="1" SubmitterName="Neurometabolic Diseases Laboratory, Bellvitge Biomedical Research Institute (IDIBELL)" OrgID="509068" OrganizationCategory="laboratory" />
        <RecordStatus>current</RecordStatus>
        <Classification DateLastEvaluated="2023-04-27">
          <ReviewStatus>criteria provided, single submitter</ReviewStatus>
          <GermlineClassification>Pathogenic</GermlineClassification>
        </Classification>
        <Assertion>variation to disease</Assertion>
        <AttributeSet>
          <Attribute Type="AssertionMethod">ACMG Guidelines, 2015</Attribute>
          <Citation>
            <ID Source="PubMed">25741868</ID>
          </Citation>
        </AttributeSet>
        <ObservedInList>
          <ObservedIn>
            <Sample>
              <Origin>germline</Origin>
              <Species TaxonomyId="9606">human</Species>
              <AffectedStatus>yes</AffectedStatus>
            </Sample>
            <Method>
              <MethodType>research</MethodType>
            </Method>
            <ObservedData>
              <Attribute Type="Description">not provided</Attribute>
            </ObservedData>
          </ObservedIn>
        </ObservedInList>
        <SimpleAllele>
          <GeneList>
            <Gene Symbol="SPG11" />
          </GeneList>
          <VariantType>Variation</VariantType>
          <AttributeSet>
            <Attribute Type="HGVS">NM_001160227.1:c.6399dup</Attribute>
          </AttributeSet>
        </SimpleAllele>
        <TraitSet Type="Disease">
          <Trait Type="Disease">
            <XRef DB="OMIM" ID="604360" Type="MIM" />
          </Trait>
        </TraitSet>
        <SubmissionNameList>
          <SubmissionName>SUB13188883</SubmissionName>
        </SubmissionNameList>
      </ClinicalAssertion>
      <ClinicalAssertion ID="8346033" SubmissionDate="2024-02-08" DateLastUpdated="2024-02-20" DateCreated="2024-02-20">
        <ClinVarSubmissionID localKey="875883|MedGen:C1858479" submittedAssembly="GRCh37" />
        <ClinVarAccession Accession="SCV004557931" DateUpdated="2024-02-20" DateCreated="2024-02-20" Type="SCV" Version="1" SubmitterName="Invitae" OrgID="500031" OrganizationCategory="laboratory" OrgAbbreviation="Invitae" />
        <RecordStatus>current</RecordStatus>
        <Classification DateLastEvaluated="2024-01-12">
          <ReviewStatus>criteria provided, single submitter</ReviewStatus>
          <GermlineClassification>Pathogenic</GermlineClassification>
          <Citation>
            <ID Source="PubMed">19105190</ID>
          </Citation>
          <Citation>
            <ID Source="PubMed">20110243</ID>
          </Citation>
          <Citation>
            <ID Source="PubMed">22154821</ID>
          </Citation>
          <Citation>
            <ID Source="PubMed">26556829</ID>
          </Citation>
          <Comment>This sequence change creates a premature translational stop signal (p.Glu2247*) in the SPG11 gene. It is expected to result in an absent or disrupted protein product. Loss-of-function variants in SPG11 are known to be pathogenic (PMID: 19105190, 20110243, 22154821, 26556829). This variant is not present in population databases (gnomAD no frequency). This variant has not been reported in the literature in individuals affected with SPG11-related conditions. ClinVar contains an entry for this variant (Variation ID: 1810401). For these reasons, this variant has been classified as Pathogenic.</Comment>
        </Classification>
        <Assertion>variation to disease</Assertion>
        <AttributeSet>
          <Attribute Type="AssertionMethod">Invitae Variant Classification Sherloc (09022015)</Attribute>
          <Citation>
            <ID Source="PubMed">28492532</ID>
          </Citation>
        </AttributeSet>
        <ObservedInList>
          <ObservedIn>
            <Sample>
              <Origin>germline</Origin>
              <Species TaxonomyId="9606">human</Species>
              <AffectedStatus>unknown</AffectedStatus>
            </Sample>
            <Method>
              <MethodType>clinical testing</MethodType>
            </Method>
            <ObservedData>
              <Attribute Type="Description">not provided</Attribute>
            </ObservedData>
          </ObservedIn>
        </ObservedInList>
        <SimpleAllele>
          <GeneList>
            <Gene Symbol="SPG11" />
          </GeneList>
          <VariantType>Variation</VariantType>
          <AttributeSet>
            <Attribute Type="HGVS">NC_000015.9:g.44859637_44859638insA</Attribute>
          </AttributeSet>
        </SimpleAllele>
        <TraitSet Type="Disease">
          <Trait Type="Disease">
            <XRef DB="MedGen" ID="C1858479" Type="CUI" />
          </Trait>
        </TraitSet>
        <SubmissionNameList>
          <SubmissionName>SUB14200314</SubmissionName>
        </SubmissionNameList>
      </ClinicalAssertion>
    </ClinicalAssertionList>
    <TraitMappingList>
      <TraitMapping ClinicalAssertionID="8346033" TraitType="Disease" MappingType="XRef" MappingValue="C1858479" MappingRef="MedGen">
        <MedGen CUI="C1858479" Name="Hereditary spastic paraplegia 11" />
      </TraitMapping>
      <TraitMapping ClinicalAssertionID="7329936" TraitType="Disease" MappingType="XRef" MappingValue="604360" MappingRef="OMIM">
        <MedGen CUI="C1858479" Name="Hereditary spastic paraplegia 11" />
      </TraitMapping>
      <TraitMapping ClinicalAssertionID="5503591" TraitType="Disease" MappingType="XRef" MappingValue="604360" MappingRef="OMIM">
        <MedGen CUI="C1858479" Name="Hereditary spastic paraplegia 11" />
      </TraitMapping>
    </TraitMappingList>
  </ClassifiedRecord>
</VariationArchive>